Metabolism of Omega-3 and Omega-6 During Healthy Aging

Metabolism of Uniformly Labelled 13C Eicosapentaenoic Acid and 13C Arachidonic Acid During Healthy Aging

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02957188

Enrollment

Registered

2016-11-07

Start date

2015-08-31

Completion date

2016-08-31

Last updated

2016-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Keywords

Eicosapentaenoic acid, Arachidonic acid, Metabolism, Healthy aging

Brief summary

The purpose of this study is to determine the kinetics of 13C-eicosapentaenoic acid (EPA) and 13C-arachidonic acid (AA) in young and older participants

Interventions

OTHER13C eicosapentaenoic acid and 13C arachidonic acid

Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.

Study design

Observational model

CASE_CROSSOVER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* six young (18-30 y old) and six older (≥ 70 y old) * healthy non medicated participants.

Exclusion criteria

* Tobacco, * malnutrition (assessed from blood albumin, haemoglobin and lipids), - * participants taking an EPA+DHA supplements or consuming more than 2 fish meals per week, * severe gastro-intestinal problems, * medication for diabetes, * thyroid disease, * renal failure, * cancer, * psychiatric difficulties or depression, * cardiovascular disease, * glucose intolerance (\>8 mmol/L in fasted samples) * chronic immune condition or inflammation (CRP \> 10 mg/l, white cell count), * recent major surgery or cardiac event, * dementia, * ongoing or past severe drug or alcohol abuse, * ongoing or past intensive physical training.

Design outcomes

Primary

Measure	Time frame
Kinetics of 13C-EPA and 13C-AA	Plasma incorporation of 13C-EPA or 13C-AA was measured from the area under the curve in young and older participants over 28 days post-dose

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026